NCT02396459View on ClinicalTrials.gov

Triac Trial II in MCT8 Deficiency Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 7, 2020

Primary Completion Date

May 13, 2024

Study Completion Date

June 30, 2026

Conditions
Allan-Herndon-Dudley Syndrome
Interventions
DRUG

Triac

Triac, individually titrated dose

Trial Locations (5)

13353

Charité - Universitätsmedizin Berlin Institut fur experimental paediatrische endokrinologie, Berlin

15006

Charles University and Motol University Hospital; The department of peadiatrics of the 2nd faculty of medicine, Prague

19104

Children's Hospital of Philadelphia, Philadelphia

97239

Oregon Health & Science University (OHSU) Doernbecher Childrens Hospital, Portland

3015 GD

Erasmus MC, Rotterdam

Sponsors

Collaborators (1)

Erasmus Medical Center
All Listed Sponsors
collaborator

Erasmus Medical Center

OTHER

lead

Rare Thyroid Therapeutics International AB

INDUSTRY